MedTrace Logo

A Study of CBP-1008 in Patients With Advanced Solid Tumor

NCT04740398 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2024-08-28

No results posted yet for this study

Summary

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1008, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

CBP-1008

CBP-1008 for injection; IV infusion; Infusion for 90 minutes

Sponsors & Collaborators

  • Coherent Biopharma (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-06
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740398 on ClinicalTrials.gov